Chairman's statement25 Apr 2024 11:08
The most worrying aspect of the Chairman's statement for me was the following para which has heightened my recent concerns. I have been very conscious of what has taken place at Redx and others - delisting from AIM and, more specifically, doing so off the back of the market failing to recognise their very strong positions (including having done some very big deals and with much cash in the bank); If more advanced companies such as those do not see the point of being on AIM then where does that leave Hemo on the future fund-raising front? Contrary and sensible arguments only by way of replies, please:
"While we accept that recent market conditions have been very difficult, we have been disappointed by the successively lower price at which we have had to carry out our fundraisings in the UK market, in the light of the progress we have made and the view taken by Prevail Partners concerning our status. The capital recently raised will undoubtedly take us materially further forward and we are now looking at a number of strategies for the future development of all three of our current product candidates."
Prof Sir Marc Feldmann AC, FRS
MB BS, PhD, FRCP, FRCPath, FAA, F Med Sci
Chairman